
    
      Design: Cross-sectional study, with long-term register-based follow-up. Study population: 160
      patients with type 1 diabetes recruited from Steno Diabetes Center Copenhagen stratified
      based on stage of diabetic kidney disease, and 50 healthy non-diabetic controls. Endpoints:
      Primary endpoint: Glycocalyx thickness, assessed as perfused boundary region. Secondary
      endpoints: Gut microbiome characterisation and markers of gastrointestinal inflammation,
      autonomic and periphery neuropathy, urine and plasma Flow Cytometry Analysis (FACS),
      metabolomics and proteomics in plasma and urine, and other potential biomarkers.
    
  